MadeMed Reviews: There Is No Monthly Plan

The one-sentence version

MadeMed publishes more price detail than most of this board — every product, both plan lengths, the per-month rate and the exact amount charged — and then does not sell the plan a first-time buyer actually wants. There is no month-to-month option anywhere on the site. The shortest way in is three months paid up front, and before any of it a comprehensive metabolic panel has to be drawn, which you arrange and pay for yourself. It grades C, 6 points out of 14, and the deduction is concentrated in one place: our rubric asks whether a single all-in figure gets you started, and at MadeMed no figure does. The grade is computed from published terms alone and cannot see who pays us.

What it is, and who it's for

MadeMed is a compounded telehealth practice with a LegitScript Verified badge and an unusually broad longevity shelf. NAD+ comes two ways — a 1,000 mg injectable dosed as eight subcutaneous shots a month, and a nasal spray at "7,500mg per bottle (500mg/mL × 15mL)" — and sermorelin comes two ways as well, a 9 mg/3 mL nightly injection and a 1,000 mcg sublingual tablet. Everything runs through an online questionnaire, a board-certified physician review inside 24 hours, and free overnight shipping.

The buyer this suits is comfortable paying a quarter in advance and wants the dose-by-dose arithmetic visible first. The buyer it does not suit is the one MadeMed itself describes — someone testing whether a protocol agrees with them. On what a first month should cost, see what longevity care costs.

What it actually costs

All figures verified on mademed.com on 26 July 2026, by toggling both plan options on each product page.

The NAD+ injection. Three months is $209/mo, "billed $627 every 3 months." Six months is $199/mo, "billed $1194 every 6 months." The product page headline reads "From $199/mo" — that is the six-month rung, not an entry price.

The nasal spray is $279/mo on three months ($837) and $269/mo on six ($1,614). Its headline says "From $279/mo", which is not even its own cheapest rate.

Sermorelin is $179/mo on three months ($537) or $169/mo on six ($1,014) as an injection; the sublingual tablet is $109/mo on three ($327) or $99/mo on six ($594).

Two plan buttons, and neither is one month. Every product page offers exactly "Quarterly" and "6-month". The cheapest way anyone can begin NAD+ therapy here is a $627 charge; the cheapest first payment on the whole longevity shelf is $327 for oral sermorelin. MadeMed's own FAQ explains why: "This is why we recommend a minimum 3-month commitment." That is a coherent clinical position. It is still a commitment made before you have taken a single dose.

Then the lab. "A CMP blood test is required before prescribing" for both NAD+ routes; injectable sermorelin requires an IGF-1 instead. You are told to "get a CMP blood test at any Labcorp or Quest location, or upload recent results" — and nowhere does the site say the panel is paid for. It is not in the "What's Included" list on any page. So the true first payment is $627 plus an unstated lab bill, and it cannot be worked out from the site at all.

Clinical oversight, billing and the pharmacy

Oversight is real and inside the price: a board-certified physician review plus a lab-guided dosing protocol, which is more than most compounded shops require. Availability is narrower than the marketing implies — the FAQ lists 23 states for both NAD+ products, not the whole country.

The billing conduct is genuinely good, and worth saying plainly on a page that is otherwise critical: "we email you 7 days before every charge with the exact amount and easy options to pause, skip, or cancel", and cancellation is "one click from your dashboard." In a category built on silent renewals, that is real protection.

Pharmacy disclosure is thinner. Every product card says only "Made in US pharmacy", and FDA's position on what that leaves unresolved is unambiguous: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed¹. The single exception sits in a nasal-spray FAQ answer benchmarking competitors, where MadeMed says it ships "Precision Pharmacy's NanoNAD+ formulation" — the only pharmacy named anywhere on the site, in a comparison answer rather than a dispensing statement. No compounding section, 503A or 503B, is claimed at any point.

The evidence behind what it sells

MadeMed's copy is more careful than most, and still goes past the trial record. The NAD+ pages promise "cellular rejuvenation for energy, clarity, and recovery", say injections "activate sirtuins — proteins that regulate longevity", and tell buyers to expect "increased energy and mental clarity within 2-4 weeks."

The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials, found effects on functional, metabolic and vascular outcomes "heterogeneous and often null or endpoint-specific", and reported that no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for these indications at all² — which speaks directly to a product sold as eight injections a month. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time³. See NAD+ for longevity and do NAD+ peptides actually work.

Sermorelin fares no better. The trial that tested exactly this protocol gave GHRH 1-29 nightly for six weeks to eleven healthy men aged 64–76: nocturnal growth hormone rose significantly, but IGF-1 did not change and DEXA-measured muscle and fat did not change⁴. The landmark review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit and significantly more adverse events⁵. MadeMed's own timeline — "improve muscle mass and recovery (weeks 4-8)" — describes outcomes that trial did not produce. See peptides for longevity.

Where it's weak, and who should skip it

Skip it if you want to try a protocol before buying a quarter of it — that option does not exist here. Skip it if the unpriced lab makes your budget unknowable, or if you are outside the 23 states. And skip it if you are buying the energy-and-clarity promise, because nothing in the trial record delivers it. If you proceed, the honest cheap entry is oral sermorelin at $327 for three months rather than the NAD+ injection at $627 — and ask what the CMP will cost before you commit to either.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). MadeMed takes the full four for its longevity line — NAD+ by two routes plus sermorelin by two more is as broad a shelf as this board has — and two for a physician review inside the price. It takes zero on price transparency, not because the numbers are hidden but because no single figure gets anyone started: the cheapest published route in is a $627 charge plus a lab bill the site never quotes. Zero for pharmacy, and zero for human support. Six of fourteen. A C, and the owner of this site has seen that grade and let it stand.

The fix is small: publish a one-month plan, and say what the CMP costs. Do both and MadeMed would jump two bands on a rubric already inclined to like it. Until then, the most literal price page on the board is attached to the least forgiving way to buy. Our other two C-graded partners are in the Try Ageless review and the Gala Health review; the full field is at our provider rankings and the scoring is in how we grade.